2002;20(12):2805–11.
11 Jordan K et al. A meta-analysis comparing
the efficacy of four 5-HT3-receptor antagonists
for acute chemotherapy-induced emesis.
Support Care Cancer 2007;15:1023–33.
12 Navari RM et al. Comparative clinical trial of
granisetron and ondansetron in the prophylaxis
of cisplatin-induced emesis. J Clin Oncol
1995;13:1242–8.
13 Italian Group for Antiemetic Research.
Ondansetron versus granisetron, both combined
with dexamethasone, in the prevention
of cisplatin-induced emesis. Ann Oncol
1995;6:805–10.
14 Navari R et al. Comparative clinical trial of
granisetron and ondansetron in the prophylaxis
of cisplatin-induced emesis. The Granisetron
Study Group. J Clin Oncol 1995;13(5):1242–8.
15 Marty M et al. Is Navoban (tropisetron) as
effective as Zofran (ondansetron) in cisplatin-
induced emesis? The French Navoban Study
Group. Anticancer Drugs 1995;6 Suppl 1:15–21.
16 Gandara DR et al. Consensus proposal
for 5HT3 antagonists in the prevention of
acute emesis related to highly emetogenic
chemotherapy. Dose, schedule, and route
of administration. Support Care Cancer
1998;6(3):237–43.
17 Dupuis LL, Nathan PC. Options for
the prevention and management of acute
chemotherapy-induced nausea and vomiting in
children. Paediatr Drugs 2003;5(9):597–613.
18 Nadaraja S et al. Palonosetron for the
prevention of nausea and vomiting in children
with acute lymphoblastic leukemia treated with
high dose methotrexate. Pediatr Blood Cancer
2012;59(5):870–3.
19 Aloxi. Summary of Product Characteristics.
www.medicines.org.uk/emc/ (accessed June
2018).
20 Aapro MS et al. A phase III, double-blind,
randomized trial of palonosetron compared
with ondansetron in preventing chemotherapy-
induced nausea and vomiting following
highly emetogenic chemotherapy. Ann Oncol
2006;17(9):1441–9.
21 Saito M et al. Palonosetron plus
dexamethasone versus granisetron plus
dexamethasone for prevention of nausea and
vomiting during chemotherapy: a double-blind,
double-dummy, randomised, comparative phase
III trial. Lancet Oncol 2009;10:115–24.
22 Bountra C et al. Anti-emetic profile of a non-
peptide neurokinin NK1 receptor antagonist,
CP-99,994, in ferrets. Eur J Pharmacol
1993;249(1):R3–4.
23 Warr DG et al. The oral NK(1) antagonist
aprepitant for the prevention of acute and
delayed chemotherapy-induced nausea and
vomiting: Pooled data from 2 randomised,
double-blind, placebo controlled trials. Eur
J Cancer 2005;41(9):1278–85.
24 Warr DG et al. Efficacy and tolerability of
aprepitant for the prevention of chemotherapy-
induced nausea and vomiting in patients with
breast cancer after moderately emetogenic
chemotherapy. J Clin Oncol 2005;23(12):
2822–30.
25 Gore L et al. Aprepitant in adolescent patients
for prevention of chemotherapy-induced nausea
and vomiting: A randomized, double-blind,
placebo-controlled study of efficacy and
tolerability. Pediatr Blood Cancer 2009;52:242–7.
26 Bošnjak SM, Gralla RJ, Schwartzberg L.
Prevention of chemotherapy-induced nausea:
the role of neurokinin-1 receptor antagonists.
Support Care Cancer 2017;Jan 20 doi: 10.1007/
s00520-017-3585-z.
27 Emend aprepitant capsules. Summary of
Product Characteristics. www.medicines.org.uk/
emc/ (accessed June 2018).
28 Ivemend. Summary of Product
Characteristics. www.medicines.org.uk/emc/
(accessed June 2018).
29 Kang HJ et al. Aprepitant for the prevention
of chemotherapy-induced nausea and vomiting
in children: a randomised, double-blind, phase 3
trial. Lancet Oncol 2015;16(4):385–94.
30 Emend powder for suspension. Summary of
Product Characteristics. www.medicines.org.uk/
emc/ (accessed June 2018).
31 Kang HJ et al. Aprepitant for the prevention
of chemotherapy-induced nausea and vomiting
in paediatric subjects: An analysis by age group.
Pediatr Blood Cancer 2018 Jun 12:e27273.
32 Clinical trials. https://clinicaltrials.gov/
(accessed June 2018).
33 Jordan K et al. Efficacy benefit of an NK1
receptor antagonist (NK1RA) in patients
receiving carboplatin: supportive evidence
with NEPA (a fixed combination of the NK1
RA, netupitant, and palonosetron) and
aprepitant regimens. Support Care Cancer
2016;24(11):4617–25.
34 Lorusso V. Management of management of
chemotherapy induced nausea and vomiting
by risk profile: role of netupitant/palonosetron.
Ther Clin Risk Manag 2016;12:917–25.
hospitalpharmacyeurope.com | 2018 | 63